3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment.
The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system.
3P and Nordic Nanovector started their collaboration in 2013 and successfully advanced Betalutin® project through these years.
The current agreement is consolidating the relationship describing how both companies will successfully progress the project up to the regulatory submission of the product including development, clinical supply and late-stage activities, such as process characterization and validation.
“Our partnership with Nordic Nanovector is a great example of how together we can achieve more than planned and succeed in the late stage of Betalutin® development,” said Dámaso Molero, General Manager at 3P Biopharmaceuticals.
He also added, “this project demonstrates how we can bring together various parties to successfully reach the project goals by using complex technologies in this challenging project.”
HH1 (Lilotomab) is a murine IgG1 antibody that targets the human glycoprotein CD37, which is found on the surface of B cells and B cell tumors.
The antibody is a component of Betalutin®, a radioimmunoconjugate molecule (RIC) which is being developed for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).